PUMA Celebrates its 75th Anniversary and Rich History in Motorsport
3.3.2023 16:16:00 EET | Business Wire | Press release
Sports company PUMA kicked off the 2023 Formula 1 season with a special panel discussion to celebrate its legacy in Motorsport culture and discuss the importance of innovations in racewear production. It was the first of a series of events to mark PUMA’s 75th anniversary.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230303005219/en/
Panel Talk ahead of the 2023 Formula 1 season to celebrate PUMAs legacy in Motorsport culture. (Photo: Business Wire)
Founded in 1948, PUMA has been at the forefront of innovation throughout its history, pushing the boundaries of what is possible in performance, functionality, and design. PUMA's rich history in motorsport dates back to 2001, when JORDAN GRAND PRIX became the first Formula 1 racing team that PUMA supplied with both footwear and clothing. Since then, PUMA has collaborated with some of the biggest names in the sport, including Michael Schumacher and Lewis Hamilton, and produced the best product for the best teams like Mercedes-AMG Petronas F1, Scuderia Ferrari and Red Bull Racing.
The panel talk was held in Bahrain on March 1 and was moderated by Noemi de Miguel, a sports journalist and television presenter for DAZN together with experts — Thomas Josnik (Global Director Motorsport, PUMA), Mick Schumacher (Mercedes-AMG Petronas F1 Team Reserve driver), Gregor Huebner (Senior Manager Sports Marketing Motorsport, PUMA) and Maurizio Sicco (Consultant in Motorsport racewear, PUMA) — they explored PUMA’s milestones in motorsport, discussed racing products from different eras, and spoke about what motorsport represents today.
PUMA’s latest racing shoes, SPEEDCAT PRO, were designed based on functionality to support drivers in their high performance on track. Years of innovation and technology packed into a single shoe, the SPEEDCAT PRO uses state of the art materials for racing. The upper and lining are made of lightweight fabric for speed, comfort, and of course fire protection. To guarantee absolute control of the pedals, the SPEEDCAT PRO comes with a low-profile rubber outsole and an EVA wedge provides just the right amount of comfort while keeping the shoe light and nimble. The SPEEDCAT PRO was built in compliance with the latest FIA Homologation Regulations for Safety Equipment (FIA Standard 8856-2018) for the best protection in racing. The SPEEDCAT PRO also includes several design elements that pay homage to PUMA's racing heritage.
“PUMA is proud to celebrate its 75th anniversary this year and also our legacy in motorsport industry”, said Thomas Josnik Global Director Motorsport at PUMA. “Innovation, speed, and technology have always been at the heart of everything we do, and this event is a tribute to our commitment to pushing boundaries and driving change in the industry.”
The event was an exciting first step in this year of celebration of 75 years of PUMA's past, present, and future in motorsport, highlighting the brand's commitment to excellence and innovation in racewear.
Event recap (YouTube): HERE
Event pictures: HERE
PUMA 75 Lewis Hamilton Interview: HERE
PUMA
PUMA is one of the world’s leading sports brands, designing, developing, selling, and marketing footwear, apparel and accessories. For 75 years, PUMA has relentlessly pushed sport and culture forward by creating fast products for the world’s fastest athletes. PUMA offers performance and sport-inspired lifestyle products in categories such as Football, Running and Training, Basketball, Golf, and Motorsports. It collaborates with renowned designers and brands to bring sport influences into street culture and fashion. The PUMA Group owns the brands PUMA, Cobra Golf and stichd. The company distributes its products in more than 120 countries, employs about 18,300 people worldwide, and is headquartered in Herzogenaurach/Germany.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230303005219/en/
Contact information
PUMA
Gudrun Cämmerer
Teamhead Global Brand PR
gudrun.caemmerer@puma.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
SES Publishes FY2025 EU Taxonomy Restatement31.7.2026 08:30:00 EEST | Press release
SES today published a restatement of its FY2025 EU Taxonomy (Article 8) disclosure. The restatement updates the FY2025 EU Taxonomy disclosure included in the 2025 Annual Report and supersedes the previously published disclosure. The FY2025 EU Taxonomy Restatement is available on the SES website: https://www.ses.com/sites/ses_v2/files/investor-files/2026-07/EU_Taxonomy_Report_Restatement_2025.pdf Follow us on: X | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where they are. With integrated multi-orbit satellites and our global terrestrial network, we deliver resilient, seamless connectivity and the highest quality video content to those shaping what’s next. Following our Intelsat acquisition, we now offer more than 100 years of combined global industry l
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom